Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.800
+0.040 (2.27%)
At close: May 12, 2025, 4:00 PM
1.800
0.00 (0.00%)
After-hours: May 12, 2025, 4:00 PM EDT
Rein Therapeutics Employees
Rein Therapeutics had 11 employees as of December 31, 2024. The number of employees decreased by 4 or -26.67% compared to the previous year.
Employees
11
Change (1Y)
-4
Growth (1Y)
-26.67%
Revenue / Employee
n/a
Profits / Employee
-$5,716,636
Market Cap
39.37M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RNTX News
- 11 days ago - Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - PRNewsWire
- 12 days ago - Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025 - PRNewsWire
- 14 days ago - Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference - PRNewsWire
- 19 days ago - Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases - PRNewsWire
- 27 days ago - Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F - PRNewsWire
- 5 weeks ago - Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PRNewsWire